首页> 美国卫生研究院文献>Clinical and Translational Science >Discovery of a Novel Circulating Biomarker in Patients with Abdominal Aortic Aneurysm: A Pilot Study Using a Proteomic Approach
【2h】

Discovery of a Novel Circulating Biomarker in Patients with Abdominal Aortic Aneurysm: A Pilot Study Using a Proteomic Approach

机译:腹主动脉瘤患者中新型循环生物标志物的发现:使用蛋白质组学方法的先导研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abdominal aortic aneurysm (AAA) is a common condition with high mortality when ruptured. Most clinicians agree that small AAAs are best managed by ultrasonographic surveillance. However, it has been stated in recent reviews that a serum/plasma biomarker that predicts AAA rupture risk would be a powerful tool in stratifying patients with small AAA. Identification of such circulating biomarkers has been to date unsuccessful. In this study, we used a proteomic approach to find new, potential plasma AAA biomarker candidates. Prefractionated plasma samples were analyzed by two‐dimensional differential in‐gel electrophoresis to identify differentially expressed proteins between four patients with small AAA and four controls without aneurysm. Protein spots that differed significantly between patients and controls were selected and identified by mass spectrometry. Three protein spots had significantly different expression between patients and controls. The most interesting finding was that patients with small AAA had increased levels of the enzyme glycosylphosphatidylinositol‐specific phospholipase D (GPI‐PLD) compared with the controls without aneurysm. In conclusion, by using a proteomic approach, this pilot‐study provides evidence of GPI‐PLD as a novel potential plasma biomarker for AAA. Clin Trans Sci 2012; Volume 5: 56–59
机译:腹主动脉瘤(AAA)破裂是常见病,死亡率高。大多数临床医生都认为,小型AAA最好通过超声检查进行管理。但是,最近的评论指出,预测AAA破裂风险的血清/血浆生物标志物将是对AAA小患者进行分层的有力工具。迄今为止,这种循环生物标志物的鉴定尚未成功。在这项研究中,我们使用了蛋白质组学方法来寻找新的,潜在的血浆AAA生物标志物候选物。通过二维差异凝胶电泳分析预分离的血浆样品,以鉴定四名AAA小患者和四名无动脉瘤的对照之间差异表达的蛋白质。选择患者和对照之间差异显着的蛋白质斑点,并通过质谱鉴定。在患者和对照之间,三个蛋白质斑点的表达明显不同。最有趣的发现是,与无动脉瘤的对照组相比,AAA小的患者的糖基磷脂酰肌醇特异性磷脂酶D(GPI-PLD)酶水平升高。总之,通过蛋白质组学方法,该试验研究提供了GPI-PLD作为AAA潜在的新型血浆生物标志物的证据。 Clin Trans Sci 2012;第5卷:56–59

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号